Hepatologist Salary Guide 2026: Liver Physician Pay, MASH Epidemic & Transplant Income

Hepatology is typically practiced as a subspecialty within gastroenterology — many hepatologists complete combined GI and hepatology fellowship training — though dedicated hepatologist positions exist at transplant programs, large health system liver disease centers, and academic medical schools. In 2026, the hepatology demand landscape has been reshaped by two major forces: the metabolic-associated steatohepatitis (MASH) epidemic, which has created an enormous wave of chronic liver disease patients requiring long-term management, and the hepatitis C cure era, which transformed HCV from a chronic disease to a curable one but simultaneously generated massive short-term visit volume for curative therapy monitoring. This guide covers hepatologist salary benchmarks, the economics of liver transplant programs, MASH drug management revenue, and the Fibroscan/elastography diagnostic model.

Hepatologist salary by setting

• Employed hepatologist (health system liver disease center): $340,000–$540,000; dedicated liver disease clinic managing cirrhosis, portal hypertension, MASH/NAFLD, autoimmune hepatitis, PBC, PSC, Wilson's disease, alpha-1 antitrypsin deficiency; some hepatologists also perform upper endoscopy for variceal screening and banding (EGD with band ligation adds significant wRVU); most common employment model
• Transplant hepatologist (academic or community transplant center): $320,000–$480,000; manages patients on the liver transplant waiting list (MELD score optimization, listing criteria, decompensation management) and post-transplant immunosuppression; UNOS-designated transplant centers require hepatology coverage; call for acute liver failure consultation and transplant decision-making adds intensity; income slightly lower than non-transplant hepatology at some centers due to academic structure, but high prestige and complex case access
• Private practice hepatologist / GI-hepatology hybrid: $360,000–$580,000; community-based or private GI group with dedicated hepatology focus; GI-hepatology hybrids who perform both endoscopy (colonoscopy, EGD) and hepatology clinic generate significantly higher wRVU and income than pure hepatology; practice in this model combines the highest wRVU elements of GI (procedural) with hepatology's growing patient panel
• Academic hepatologist (medical school faculty): $280,000–$420,000; fellowship training, NIH-funded liver research — MASH pathophysiology, liver fibrosis biology, viral hepatitis, liver cancer (HCC) surveillance; lower nominal pay but research supplementation and access to clinical trial patient populations are significant draws; liver transplant research at academic programs is particularly active
• Telemedicine hepatology: $260,000–$380,000; virtual hepatology consultation for rural health systems without in-person hepatologist; MASH management, cirrhosis compensation monitoring, HCC surveillance protocol management — many elements manageable via telemedicine; growing segment as liver disease burden in rural markets exceeds in-person specialist access

MASH epidemic and hepatology demand

Metabolic-associated steatohepatitis (MASH — formerly NASH) is now the leading cause of liver transplantation in the United States and the fastest-growing chronic liver disease globally. The hepatology demand implications are profound:

• Patient population scale: Approximately 115 million Americans have fatty liver disease (MASLD); 20–30 million have MASH; an estimated 3–5 million have advanced fibrosis or cirrhosis from MASH; this patient population needs ongoing hepatology monitoring, fibrosis staging, and increasingly, pharmacotherapy management
• Resmetirom (Rezdiffra): First FDA-approved MASH drug (March 2024); thyroid hormone receptor beta agonist; indicated for non-cirrhotic MASH with moderate-to-advanced fibrosis (F2-F3); hepatologists prescribing and monitoring Rezdiffra patients will become a major component of liver disease practice — generating longitudinal patient visits, lab management, and drug counseling billing
• GLP-1 agonists for MASH: Semaglutide (Ozempic/Wegovy) and tirzepatide have demonstrated MASH histological resolution in phase III trials; hepatologists are increasingly co-managing metabolic disease with endocrinology and primary care to address the root cause of MASH; multi-specialty MASH programs are being built at academic centers and large health systems
• HCC surveillance: Every cirrhotic patient requires semi-annual HCC surveillance (abdominal ultrasound ± AFP); the growing cirrhosis population from MASH generates a massive ongoing surveillance billing stream for hepatologists; HCC diagnosis and treatment coordination adds further visit volume

Hepatitis C economics — the curative therapy era

Direct-acting antiviral (DAA) therapy has achieved cure rates of 95%+ for hepatitis C infection, fundamentally changing hepatology economics:

• DAA prescribing: Sofosbuvir/velpatasvir (Epclusa), glecaprevir/pibrentasvir (Mavyret), sofosbuvir/ledipasvir (Harvoni) — 8–12 week courses; specialty pharmacy-prescribed; hepatologists managing HCV patients generate substantial E&M billing during treatment and follow-up; SVR (sustained virologic response) confirmation visit closes the HCV treatment episode
• Contracted HCV cure programs: Some hepatologists have partnered with jails, prisons, and addiction treatment centers to manage HCV cure programs in high-prevalence populations; these contracted programs generate E&M volume beyond the standard clinic model
• Post-cure management: Even cured patients with pre-existing cirrhosis require ongoing surveillance (HCC and variceal screening) indefinitely; HCV cure has not eliminated the need for hepatology monitoring — it has shifted the patient population from active treatment to long-term surveillance

Liver transplant program income and UNOS requirements

Hepatologists working in liver transplant programs operate in the most complex and regulated segment of hepatology:

• UNOS transplant center requirements: UNOS-designated liver transplant centers must maintain minimum case volumes (currently 10 transplants/year minimum), outcomes tracking, and multidisciplinary team requirements; hepatologists must be available to manage listing decisions, acute decompensation, and post-transplant care as part of the designated team
• Post-transplant management billing: The immediate post-transplant period (first year) generates high-frequency clinic visit billing; tacrolimus level monitoring, rejection surveillance, infection prophylaxis management, and metabolic syndrome management in liver transplant recipients create significant ongoing E&M volume
• Acute liver failure (ALF) consultation: ALF from acetaminophen toxicity, viral hepatitis, drug-induced liver injury, and Wilson's disease requires emergent hepatology consultation and potential urgent listing; most ALF consultations occur in academic centers with transplant programs; complex decision-making with high urgency

Fibroscan and liver elastography revenue

Transient elastography (FibroScan, Echosens) and shear wave elastography are non-invasive liver fibrosis assessment tools that generate in-office diagnostic revenue for hepatology practices:

• FibroScan professional and technical billing: CPT 91200; professional fee $80–$160; technical component at physician-owned device $200–$500; total per-study revenue $280–$660 for practices that own the device and bill both components
• Device cost and ROI: FibroScan device (controlled attenuation parameter + elastography model) costs $80,000–$120,000; a hepatology practice performing 5–10 Fibroscans/day achieves ROI within 12–24 months and generates $100,000–$200,000/year in diagnostic revenue at full volume
• Point-of-care use: Fibroscan performed in the hepatology office allows same-day fibrosis staging without referral to radiology or separate scheduling; improves patient convenience and captures the diagnostic revenue in-house rather than at the hospital radiology department

Geographic variation in hepatologist compensation

• Academic transplant centers (UCLA, UCSF, Penn, Columbia, Mayo): $280,000–$440,000; highest fellowship prestige and complex case access; lower nominal pay; research supplementation significant for NIH investigators
• Sun Belt community and health system hepatology (FL, TX, AZ): $370,000–$560,000; high MASH burden and large diabetic/obese patient population; growing community liver disease center programs; strong GI-hepatology private practice culture in FL and TX
• Midwest / Southeast: $330,000–$520,000; academic and community balance; strong alcohol-related liver disease burden in some Midwest markets; transplant center distribution relatively concentrated
• Rural shortage areas: $310,000–$500,000; significant hepatology access deficit in rural markets; telemedicine hepatology partially fills the gap but in-person endoscopy for variceal screening and elastography remain barriers to fully virtual care

What we see at Ava Health

Hepatology demand is driven by two parallel forces — MASH patients needing their first liver specialist, and the ongoing management of the cirrhosis population that has been accumulating for decades. The MASH drug era (Rezdiffra launch and GLP-1 evidence building) is beginning to create a new category of hepatology work: pharmacotherapy management for MASH patients who previously had no disease-modifying treatment. For hepatologists in our network evaluating their career options, the GI-hepatology hybrid model — where the physician performs both endoscopy and hepatology clinic — consistently generates the highest income by combining high-wRVU procedural billing with the growing hepatology patient panel. Pure hepatologists without endoscopy have a lower income ceiling but often access the most complex liver disease cases.

Related: Gastroenterologist Salary Guide, Internal Medicine Physician Salary Guide, Endocrinologist Salary Guide, Physician Assistant Salary Guide.